The Src inhibitor peptide TAT-Cx43<sub>266-283</sub> improves survival in an intracranial murine model of lung cancer brain metastasis.

It should be mentioned that the activities of Src (SRC Proto-Oncogene Non-Receptor Tyrosine Kinase, Src), mTor (Mammalian Target of Rapamycin Kinase, mTOR), Mapk14 (Mitogen-Activated Protein Kinase 14, p38), Csnk2a1 (Casein kinase II, Cka2), and Cdk1 (Cyclin Dependent Kinase 1, Cdk1) were also decreased by TAT-Cx43 266-283 , although the extent of inhibition did not reach statistical significance.

also in 111,027 other papers